98%
921
2 minutes
20
Ethnopharmacological Relevance: Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer (BC), is more sensitive to ferroptosis than other subtypes. Xihuang pill (XHP) has been extensively used in Chinese clinical practice as an adjuvant therapy for TNBC. However, the underlying mechanisms of XHP in TNBC treatment remain incompletely elucidated.
Aim Of The Study: This study aimed to investigate the anti-TNBC activity of XHP and further clarify its underlying molecular mechanism.
Materials And Methods: An integrated strategy combining network pharmacology with UHPLC-QqQ-MS-based metabolomics was used to identify the active compounds and genes related to XHP that exert anti-TNBC effects by modulating ferroptosis-related protein ubiquitination modifications. In vivo, the therapeutic effects of XHP on TNBC were investigated via a subcutaneous xenograft model. In vitro, we evaluated the effects of XHP on the cell proliferative capacity following DCFH-DA, JC-1, and C11-BODIPY probes, transmission electron microscopy, Fe, MDA, and GSH assay kits were used to detect ferroptosis-related indicators. Potential mechanisms were assessed using western blotting, immunofluorescence, immunohistochemistry, and ubiquitination assays.
Results: OTUB1, SLC7A11, SLC3A2, and GPX4 were identified by network pharmacology in combination with UHPLC-QqQ-MS-based metabolomics as the key targets by which XHP exerts anti-TNBC effects by modulating ferroptosis-related protein ubiquitination modifications. β-boswellic acid, α-boswellic acid, deoxycholic acid, choline, chenodeoxycholic acid, and muscone were identified as key compounds. The experimental results demonstrate that XHP suppresses TNBC cell proliferation, invasion, and migration, safely inhibits tumour growth, with elevated Fe, LPO and ROS levels, and enhances GSH depletion and mitochondrial damage. Our results further confirmed that XHP exerts its anti-TNBC effects by inducing cell ferroptosis, as ferrostatin-1 was found to rescue XHP-induced inhibition of cell proliferation. Mechanistically, XHP promotes the degradation of SLC7A11 via the proteasomal pathway by suppressing OTUB1-mediated deubiquitination, thereby inducing system Xc/GPX4 axis-dependent ferroptosis.
Conclusions: Our study demonstrated that XHP may exert anti-TNBC effects partly by inhibiting OTUB1-mediated deubiquitination of SLC7A11, thereby inducing system Xc/GPX4 axis-dependent ferroptosis. This study provides a foundation for developing potential products from XHP plant materials for the TNBC treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jep.2025.120456 | DOI Listing |
Anticancer Agents Med Chem
August 2025
School of Medicine, Suzhou Vocational Health College, Suzhou, China.
Introduction: Ursolic acid (UA) exhibits antitumor activity; however, its effects and mechanisms on triple-negative breast cancer (TNBC) cells are not well understood. The present study aimed to explore the anti- TNBC mechanisms of UA by network pharmacology and experimental validation.
Methods: TNBC cell lines MDA-MB-231 and BT-549 cells were treated with UA.
Int J Oncol
November 2025
Department of Ultrasound, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.
Triple‑negative breast cancer (TNBC) is an aggressive malignancy with limited treatment options, leading to poor clinical outcomes and the need for novel therapeutic approaches. Nintedanib, a United States Food and Drug Administration‑approved multi‑kinase inhibitor with anti‑fibrotic and anti‑angiogenic properties, has shown promise in cancer treatment. However, its precise molecular effects on TNBC have not yet been fully elucidated.
View Article and Find Full Text PDFJ Ethnopharmacol
August 2025
School of Traditional Chinese Medicine, Jinan University, Guangzhou, Guangdong Province, 510632, China; The Oncology Department, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, 510632, China. Electronic address:
Ethnopharmacological Relevance: Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer (BC), is more sensitive to ferroptosis than other subtypes. Xihuang pill (XHP) has been extensively used in Chinese clinical practice as an adjuvant therapy for TNBC. However, the underlying mechanisms of XHP in TNBC treatment remain incompletely elucidated.
View Article and Find Full Text PDFIOSR J Dent Med Sci
June 2025
Department Of Natural And Pharmaceutical Sciences. Elizabeth City State University Campus Of The University Of North Carolina. Elizabeth City, North Carolina- 27909, USA.
The incidence of triple-negative breast cancer (TNBC) is approximately 10-15% of all breast cancer cases around the world. It is important to search for novel therapeutic agents against TNBC since this form of cancer is a leading cause of death in women worldwide. Various genetic mutations in TNBC patients have been identified.
View Article and Find Full Text PDFFront Chem
July 2025
College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Background: Due to the lack of effective treatment methods and targeted drugs, triple-negative breast cancer (TNBC) is not only difficult to treat clinically, but also has a poor prognosis for patients. This study aims to develop novel anti-TNBC drug candidates by designing 90 derivatives of 3,4--lupane triterpene derivatives, a natural product of the genus Eleutherogenus.
Methods: Firstly, 90 derivatives were synthesized and screened, and the compound I-27 showed excellent cytotoxicity (IC=1.